BioSpace News Archive

Biotech Beach

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) today hosted an investor event highlighting neffy® (epinephrine nasal spray), an investigational new drug, for the treatment of Type I allergic reactions.

March 7, 2024
·
11 min read
Business

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024.

March 7, 2024
·
1 min read
Business

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial results for the fourth quarter and full-year of 2023 and provided a business update.

March 7, 2024
·
15 min read
BioForest

Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

Xtant Medical Holdings, Inc. announced that the Company’s revolving credit agreement with MidCap Financial Trust was amended to increase the commitment from $8.0 million to $17.0 million.

March 7, 2024
·
4 min read
Business

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2023, and initiated financial guidance for full year 2024.

March 7, 2024
·
19 min read
Drug Development

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Kronos Bio, Inc. announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Company’s pipeline, including the ongoing phase 1/2 study of KB-0742 following the review of additional positive preliminary safety and efficacy data.

March 7, 2024
·
7 min read
Business

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced its financial results for the fourth quarter ended December 31, 2023, and provided corporate updates.

March 7, 2024
·
15 min read
Business

IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments.

March 7, 2024
·
9 min read
Business

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update.

March 7, 2024
·
7 min read
Business

Medtronic announces cash dividend for fourth quarter of fiscal year 2024

The board of directors of Medtronic plc on Thursday, March 7, 2024, approved the company’s cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share.

March 7, 2024
·
2 min read